NZ503401A - Use of interferon-beta (IFN-B) genes for the treatment of cancer - Google Patents

Use of interferon-beta (IFN-B) genes for the treatment of cancer

Info

Publication number
NZ503401A
NZ503401A NZ503401A NZ50340198A NZ503401A NZ 503401 A NZ503401 A NZ 503401A NZ 503401 A NZ503401 A NZ 503401A NZ 50340198 A NZ50340198 A NZ 50340198A NZ 503401 A NZ503401 A NZ 503401A
Authority
NZ
New Zealand
Prior art keywords
interferon
beta
ifn
genes
cancer
Prior art date
Application number
NZ503401A
Other languages
English (en)
Inventor
Xiao-Qiang Qin
James G Barsoum
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NZ503401A publication Critical patent/NZ503401A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ503401A 1997-08-29 1998-08-25 Use of interferon-beta (IFN-B) genes for the treatment of cancer NZ503401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (1)

Publication Number Publication Date
NZ503401A true NZ503401A (en) 2003-01-31

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503401A NZ503401A (en) 1997-08-29 1998-08-25 Use of interferon-beta (IFN-B) genes for the treatment of cancer

Country Status (24)

Country Link
EP (1) EP1007717B8 (enExample)
JP (3) JP4124565B2 (enExample)
KR (1) KR100699285B1 (enExample)
CN (1) CN100342019C (enExample)
AT (1) ATE316145T1 (enExample)
AU (1) AU740428B2 (enExample)
BR (1) BR9812138A (enExample)
CA (1) CA2300480C (enExample)
CY (1) CY1105029T1 (enExample)
CZ (2) CZ297314B6 (enExample)
DE (1) DE69833264T2 (enExample)
DK (1) DK1007717T3 (enExample)
EA (1) EA003256B1 (enExample)
EE (1) EE04873B1 (enExample)
ES (1) ES2257817T3 (enExample)
HU (1) HU224422B1 (enExample)
IL (2) IL134593A0 (enExample)
IS (1) IS2318B (enExample)
NO (1) NO20000990L (enExample)
NZ (1) NZ503401A (enExample)
PT (1) PT1007717E (enExample)
SK (1) SK286821B6 (enExample)
TR (1) TR200000532T2 (enExample)
WO (1) WO1999010516A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) * 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CN114630670B (zh) * 2019-06-01 2025-03-11 西韦克生物技术有限责任公司 用于将基因编辑系统递送至真核细胞的细菌平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
TR200000532T2 (tr) 2000-11-21
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
IS2318B (is) 2007-11-15
HUP0002913A3 (en) 2003-08-28
CN100342019C (zh) 2007-10-10
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
IL134593A (en) 2007-06-17
JP2005225888A (ja) 2005-08-25
NO20000990D0 (no) 2000-02-28
CA2300480C (en) 2010-01-05
CA2300480A1 (en) 1999-03-04
KR100699285B1 (ko) 2007-03-26
BR9812138A (pt) 2000-07-18
JP4219335B2 (ja) 2009-02-04
DE69833264D1 (de) 2006-04-06
WO1999010516A2 (en) 1999-03-04
EE04873B1 (et) 2007-08-15
DE69833264T2 (de) 2006-09-28
ATE316145T1 (de) 2006-02-15
PT1007717E (pt) 2006-06-30
IS5374A (is) 2000-02-11
CN1271391A (zh) 2000-10-25
EA003256B1 (ru) 2003-02-27
SK286821B6 (sk) 2009-06-05
KR20010023511A (ko) 2001-03-26
AU9205198A (en) 1999-03-16
HU224422B1 (hu) 2005-08-29
JP2004155786A (ja) 2004-06-03
CY1105029T1 (el) 2010-03-03
WO1999010516A3 (en) 1999-05-06
EE200000102A (et) 2000-12-15
CZ2000733A3 (cs) 2000-06-14
EP1007717A2 (en) 2000-06-14
JP4124565B2 (ja) 2008-07-23
HUP0002913A2 (hu) 2000-12-28
JP2001514010A (ja) 2001-09-11
JP3953458B2 (ja) 2007-08-08
EA200000270A1 (ru) 2000-10-30
ES2257817T3 (es) 2006-08-01
EP1007717B8 (en) 2006-05-03
CZ299095B6 (cs) 2008-04-23
NO20000990L (no) 2000-05-02
CZ297314B6 (cs) 2006-11-15
DK1007717T3 (da) 2006-05-29
SK2482000A3 (en) 2000-08-14

Similar Documents

Publication Publication Date Title
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
IL109092A0 (en) Tumor suppressor gene, protein expressed thereby, vectors containing said gene, and use of said vector and protein in cancer treatment
AU1750297A (en) Humanized green fluorescent protein genes and methods
EP0998569A4 (en) POLYNUCLEOTIDE ENCODING POLYPEPTIDE HAVING HEPARANASE ACTIVITY AND ITS EXPRESSION BY TRANSDUCTED CELLS
DE3165463D1 (en) Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
PL308122A1 (en) Viral vectors and their application in genic therapy
PT1027094E (pt) Novo aparelho e método para infusão pélvica isolada
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA81103B (en) Dna sequences ,recombinant dna molecules dna molecules and processes for producing human interferon -like polypeptides
NZ503401A (en) Use of interferon-beta (IFN-B) genes for the treatment of cancer
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
OA09116A (en) Novel protein, sequences containing the gene therefore vectors, methods of preparation and use.
PL319040A1 (en) Modified proteins
IL117116A0 (en) A medical composition for the in vivo transfection and expression of exogenes
AU3002497A (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
EP0129582A4 (en) BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS FOR ORAL ADMINISTRATION.
IL88095A0 (en) Dna sequences,proteins and gene preparations
DK606088A (da) Rekombinant-dna-udtrykkelsesvektorer og dna-forbindelser, der koder for isopenicillin n synthetase
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
GR3019347T3 (en) Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
NZ233672A (en) Alpha amylase-pullulanase enzyme produced by recombinant techniques and its dna coding sequence
LTIP477A (en) Secondary metabolism activation (saf) factor polypeptide, gene,promoter and use for expression in streptomyces
IL83435A (en) Dna construct for expression of genes in yeast, an expression vector containing it and yeast transformed with said expression vector

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired